<DOC>
	<DOCNO>NCT00671723</DOCNO>
	<brief_summary>Despite lack trial prove efficacy DNase non cystic fibrosis patient , currently heavily use population . In fact , per evidence barcode scan via Meditech computer system OU Medical Center 93 % DNase prescribed 2005 non Cystic fibrosis patient estimate yearly cost $ 341,968.15.In vitro study show effect Dnase minimal sputum viscosity compare Hypertonic saline . Furthermore recent study hypertonic saline cystic fibrosis patient show inexpensive safe therapy precede bronchodilator patient cystic fibrosis . We hereby propose prospective randomize trial compare efficacy hypertonic saline , DNase , vs. normal saline treatment atelectasis non cystic fibrosis , mechanically ventilated patient .</brief_summary>
	<brief_title>Dornase Alpha Versus Hypertonic Saline Lung Atelectasis Non-Cystic Fibrosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Atelectasis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>1 . Patient invasive mechanical ventilation 2 . New Onset ( &lt; 48 hour ) lobar multilobar lung atelectasis base CXR 1 . Asthma 2 . Severe COPD ( FEV1 &lt; 30 % ) 3 . Pneumothorax massive pleural effusion , think cause atelectasis 4 . Lobar atelectasis secondary compressive tumor . 5 . Severe hypoxemia ( PaO2/FiO2 &lt; 75 ) 6 . Hemodynamic Instability 7 . Cystic fibrosis patient 8 . Allergy DNase 9 . Patients Acetylcysteine 10 . Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Atelectasis</keyword>
</DOC>